TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately.
About Acerus
Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health.
Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.
Company Contact
Naveed Manzoor
Chief Financial Officer
ir@aceruspharma.com
Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…
PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…
IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…
CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…
The Life Sciences BPO Market is expanding rapidly, driven by rising R&D costs, increasing regulatory…
Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…